Robbins LLP is Investigating the Officers and Directors of Omega Therapeutics, Inc. (OMGA)

Robbins LLP is investigating Omega Therapeutics, Inc. (NASDAQ: OMGA) to determine whether certain Omega Therapeutics, Inc. officers and directors violated securities laws and breached fiduciary duties to shareholders by allowing controlling shareholder Flagship Pioneering, Inc. to unduly benefit from Company assets. Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. 

In early 2023, a subsidiary of Flagship reached out to Omega, proposing they work together to create a new obesity treatment for Novo Nordisk. The collaboration would rely heavily on Omega's technologies, expertise, and IP. If a drug candidate were to be selected for pre-clinical research, Omega would grant a worldwide license to Novo Nordisk. Flagship's main contribution was to develop a lipid nanoparticle delivery vehicle for the drug to enter fat tissues, which was of secondary importance, as there are numerous alternatives to Flagship's technology. The companies struck a 50/50 split of the proceeds, which may be unfair to Omega and disproportionately outsized compared to Flagship's overall contribution. We are investigating whether Flagship – as controlling shareholder – exerted its control and influence over Omega and the Board to exploit Omega's assets for its own gain.

What Now: Omega Therapeutics, Inc. (OMGA) shareholders have legal options. If you own shares of Omega Therapeutics, Inc. and have lost money in your investment, contact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.